Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](PTC Therapeutics)"
Count: 68
Selected: 0
| NCT ID | Title |
|---|
| NCT05358717 | A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) | ||
| NCT05349721 | Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS | ||
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | ||
| NCT05218655 | A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease | ||
| NCT05166161 | A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria | ||
| NCT05099640 | A Study of PTC923 in Participants With Phenylketonuria | ||
| NCT04903288 | A Study of SmartFlow® Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants | ||
| NCT04577352 | A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia | ||
| NCT04439071 | A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) | ||
| NCT04378075 | A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy | ||
| NCT04336826 | A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) | ||
| NCT04117880 | A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia | ||
| NCT03796637 | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren | ||
| NCT03783923 | A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) | ||
| NCT03761095 | A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | ||
| NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | ||
| NCT03712124 | A Study of CNSA-001 in Women With Diabetic Gastroparesis | ||
| NCT03648827 | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) | ||
| NCT03642145 | A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD) | ||
| NCT03519711 | A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia | ||
| NCT03179631 | Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy | ||
| NCT02819557 | Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy | ||
| NCT02647359 | Study of Ataluren in Participants With Nonsense Mutation Aniridia | ||
| NCT02592941 | Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy | ||
| NCT02485431 | Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers | ||
| NCT02460679 | Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS) | ||
| NCT02456103 | Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis | ||
| NCT02409004 | Effects of Rifampin on the Pharmacokinetics of Ataluren | ||
| NCT02404480 | PTC596 in Patients With Advanced Solid Tumors | ||
| NCT02369731 | Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) | ||
| NCT02352896 | Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome | ||
| NCT02295748 | An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort | ||
| NCT02286635 | Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort | ||
| NCT02286622 | A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics | ||
| NCT02286609 | A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics | ||
| NCT02251600 | A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy | ||
| NCT02139306 | Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF) | ||
| NCT02107859 | Study of Ataluren (PTC124) in Cystic Fibrosis | ||
| NCT02090959 | An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy | ||
| NCT01826487 | Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) | ||
| NCT01728064 | Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia | ||
| NCT01721733 | Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome | ||
| NCT01557400 | Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada | ||
| NCT01370447 | EPI-743 for Mitochondrial Respiratory Chain Diseases | ||
| NCT01247207 | Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) | ||
| NCT01141075 | Ataluren for Nonsense Mutation Methylmalonic Acidemia | ||
| NCT01140451 | Extension Study of Ataluren (PTC124) in Cystic Fibrosis | ||
| NCT01009294 | Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD) | ||
| NCT00947193 | Study of Ataluren (PTC124) in Hemophilia A and B | ||
| NCT00911248 | PTC299 for Treatment of Neurofibromatosis Type 2 |
